PAK4-LIMK1-Cofilin信号通路对非小细胞肺癌迁移及侵袭能力的影响

 目的: 探讨p21活化激酶4(PAK4)对非小细胞肺癌(NSCLC)侵袭和迁移能力的影响及相关机制。方法: PAK4-siRNA或阴性对照转染A549和NCI-H520细胞株,实时荧光定量PCR和Western blot分别检测细胞PAK4 mRNA和蛋白表达水平,Transwell小室法检测其对细胞侵袭和迁移能力的影响;Western blot检测其LIMK1、cofilin及其磷酸化水平;免疫共沉淀检测PAK4和LIMK1蛋白是否直接绑定;体外激酶分析实验检测LIMK1是否是PAK4的激酶底物;Western blot检测10例非小细胞肺癌组织中PAK4和磷酸化LIMK1的相关性;PAK4-siRNA和LIMK1质粒共转染A549和NCI-H520细胞后观察细胞迁移和侵袭能力变化。结果: 沉默PAK4后A549和NCI-H520细胞迁移和侵袭能力明显减弱(P<0.05);LIMK1和cofilin蛋白水平无显著变化,而磷酸化LIMK1和磷酸化cofilin水平显著下调;免疫共沉淀结果示PAK4与LIMK1相互绑定;激酶分析实验结果显示,激酶缺陷型PAK4(K350M)使LIMK1磷酸化的作用显著低于野生型PAK4或活化型PAK4(S445N)(P<0.05)。Western blot检测结果示非小细胞肺癌组织中PAK4表达上调的程度与磷酸化LIMK1含量呈正相关(P<0.05);PAK4-siRNA和LIMK1质粒共转染A549和NCI-H520细胞后,迁移和侵袭细胞数均高于PAK4-siRNA转染组(P<0.05)。结论: PAK4通过直接磷酸化LIMK1而促进非小细胞肺癌的迁移及侵袭能力。     

p21活化激酶6对人非小细胞肺癌A549细胞侵袭及迁移能力的影响

 目的：探讨p21活化激酶6（PAK6）对非小细胞肺癌侵袭及迁移能力的影响及机制研究。方法：实时荧光定量PCR检测人非小细胞肺癌A548细胞、人支气管上皮细胞、非小细胞肺癌组织及癌旁组织中PAK6 mRNA的表达。A549细胞分别转染siRNA-PAK6（siPAK6组）和阴性对照（对照组）,实时荧光定量PCR技术检测PAK6 mRNA,Western blotting检测PAK6表达量;并行体外迁移及侵袭实验,检测转染siRNA-PAK6对A549细胞侵袭及迁移能力的影响;共聚焦显微镜观察细胞骨架的改变。结果：A549细胞中PAK6 mRNA的表达量明显高于人支气管上皮细胞中PAK6 mRNA的表达量（3.50±1.16 vs 1.12±0.42,P<0.05）,非小细胞肺癌组织中PAK6 mRNA的表达量明显高于癌旁组织中PAK6 mRNA的表达量（5.13±1.33  vs 1.08±0.37,P<0.05）。A549细胞转染siPAK6后,PAK6蛋白表达量下降72%（P<0.05）,PAK6 mRNA水平明显下降（3.72±0.75 vs  0.69±0.21,P<0.05）。A549细胞转染siPAK6组侵袭及迁移出的细胞数量明显少于对照组(P<0.05)。siPAK6组A549细胞骨架应力纤维减少明显,肌动蛋白皱缩。结论：PAK6通过细胞骨架的重构影响非小细胞肺癌的侵袭及迁移能力。     

过表达miR-10b促进肺癌细胞系A549增殖

目的探讨非小细胞肺癌(NSCLC)患者肺癌及癌旁组织中miR-10b(miR-10b)表达水平及miR-10b是否通过调控锌指转录蛋白基因(KLF4)对肺癌细胞系A549恶性化的影响。方法 40例NSCLC患者病理切片,原位杂交检测肺癌及癌旁组织中miR-10b的表达量;对肺癌细胞系A549转染miR-10b mimics后,CCK-8法检测肺癌细胞增殖;real-time PCR及Western blot检测KLF4 mRNA及蛋白水平;软琼脂克隆形成实验检测过表达miR-10b对A549细胞的肿瘤恶性化程度的影响。结果肺癌细胞A549及肺癌组织中miR-10b的表达量分别高于正常肺上皮细胞16HBE及癌旁组织;过表达miR-10b模拟物的A549细胞中,KLF4蛋白水平显著下降(P0.05);过表达的miR-10b可显著增加A549细胞的增殖速度及在软琼脂内的成瘤性。结论 miR-10b在不同类型细胞及组织中具有分布差异性、可能是通过抑制KLF4的表达促进肺癌细胞增殖及恶性化。     

PIK3CA基因对人非小细胞肺癌A549细胞侵袭及迁移能力的影响

目的探讨PIK3CA基因对非小细胞肺癌侵袭及迁移能力的影响及可能机制。方法实时荧光定量PCR检测非小细胞肺癌组织、癌旁组织、非小细胞肺癌A549细胞与人支气管上皮细胞PIK3CA mRNA的表达,构建靶向PIK3CA基因的si RNA质粒,并转染至非小细胞肺癌A549细胞,实时荧光定量PCR技术与Westem blot方法分别检测PIK3CA mRNA与蛋白表达的变化,利用Transwell实验检测转染后细胞侵袭和转移能力的变化,Westem blot方法检测转染后A549细胞p-Akt蛋白表达变化。结果与癌旁正常组织比较,PIK3CA mRNA和蛋白表达水平在非小细胞肺癌组织显著上升(P0.05),A549细胞中PIK3CA mRNA和蛋白表达水平明显高于人支气管上皮细胞(P0.05)。PIK3CA基因沉默6h,A549细胞PIK3CA mRNA和蛋白表达水明显下降(P0.05);PIK3CA基因沉默48h,A549细胞侵袭和转移能力显著降低,p-Akt蛋白表达显著降低(P0.05)。结论 PIK3CA基因能够降低非小细胞肺癌侵袭及迁移能力,其作用机制可能与调控p-Akt蛋白表达有关。     

ANKRD49在非小细胞肺癌的表达

目的探讨ANKRD49蛋白质在非小细胞肺癌中的表达及其与多种临床参数的关系。方法收集75例非小细胞肺癌患者的癌组织及癌旁组织,制成组织芯片后用免疫组织化学法检测ANKRD49在癌组织及癌旁组织中的表达,同时分析ANKRD49的表达与肺癌不同临床参数之间的关系。用免疫印迹技术分析ANKRD49蛋白质在人气道上皮细胞及多种不同肺癌细胞系中的表达。结果 ANKRD49在肺癌组织中的表达率为82.67%,显著高于癌旁组织的49.33%(P0.05);ANKRD49在低分化肺癌组织中的表达为80%,高于高分化肺癌组织的42.6%(P0.05);ANKRD49仅在肺腺癌细胞系A549和NCI-H1650中表达,而在人正常气道上皮细胞及其他肺癌细胞系中无表达。结论 ANKRD49可能参与非小细胞肺癌的发生发展过程。     

长链非编码RNA MIAT在非小细胞肺癌中的表达及功能研究

目的:研究长链非编码RNA心肌梗死相关转录本(MIAT)在非小细胞肺癌(NSCLC)组织及细胞系中的表达情况及其对NSCLC细胞功能的影响。方法:利用Gene Expression Omnibus(GEO)数据库提取GSE19804和GSE30219数据集的生物信息学资料和临床预后资料,分析MIAT在NSCLC组织和正常肺组织中的表达差异,以及MIAT表达水平与NSCLC患者生存期的关系;用q PCR检测25对NSCLC肿瘤组织和其癌旁组织,以及NSCLC细胞系A549、NCI-H266和NCI-H1299及人正常支气管上皮细胞系HBE中MIAT的表达情况;将MIAT si RNA(si-MIAT)和对照序列(si-NC)分别转染NSCLC细胞系A549,采用流式细胞术、CCK-8实验和细胞集落形成实验检测2组细胞的增殖情况,并且用q PCR和Western blot实验检测2组细胞中细胞周期蛋白D1(cyclin D1)和细胞周期蛋白依赖性激酶抑制剂1A(CDKN1A)的表达情况。结果:GSE19804数据集分析显示MIAT在NSCLC组织中的表达高于正常肺组织(P0.05),GSE30219数据集分析显示MIAT高表达患者的生存期显著短于低表达患者(P0.01)。此外,与癌旁正常组织和HBE细胞相比较,NSCLC组织和细胞系中MIAT的表达水平升高(P0.05);si-MIAT组A549细胞中MIAT表达水平明显低于si-NC组(P0.01),且细胞活力和细胞集落数均低于siNC组,差异均有统计学意义(P0.05);同时,相较于si-NC组,si-MIAT组cyclin D1的表达受到明显抑制(P0.05),而CDKN1A的表达明显升高(P0.05)。结论:NSCLC组织及细胞系中MIAT呈高表达,沉默MIAT表达可明显抑制NSCLC恶性增殖的表型。MIAT可作为NSCLC靶向治疗的潜在靶标。     

Wip1在非小细胞肺癌组织及细胞中的表达

目的： 检测肺癌组织和3种肺癌细胞中Wip1的表达水平,探讨肺癌中Wip1的表达水平与其各种临床病理特征之间的关系。方法: 利用实时荧光定量PCR检测44例肺癌及相应正常肺组织中Wip1 mRNA的表达,分析Wip1 mRNA表达与各临床病理参数之间的关系;利用实时荧光定量PCR的方法检测人肺腺癌细胞A549、人鳞癌细胞NCI-1299、人大细胞肺癌细胞NCI-H460和人正常支气管上皮细胞HBE中Wip1 mRNA的表达量,进行相对定量分析。结果: 44例非小细胞肺癌及相应正常肺组织均有Wip1 mRNA的表达,其中17例肺癌中Wip1 mRNA高表达,占38.6%,两者表达差异显著(ratio=2.1644±1.3940,P＜0.05);分化程度低的肿瘤细胞Wip1 mRNA表达量显著高于分化程度高者（P<0.05）。3种肺癌细胞中的Wip1 mRNA表达量显著高于正常支气管上皮细胞,差异显著(均P＜0.05)。结论: Wip1mRNA在非小细胞肺癌中过表达,可能与肿瘤发生有关,有望成为非小细胞肺癌基因治疗的新靶点。Wip1 mRNA在非小细胞肺癌中的表达与肿瘤细胞分化程度有关,可能成为确定肿瘤恶性程度的分子生物学参考指标。     

人原发性肺癌组织中Rab相互作用溶酶体蛋白基因甲基化检测及其临床意义

目的 分析Rab相互作用溶酶体蛋白(RILP)在肺癌患者癌组织及肺癌细胞系中的表达及其甲基化情况,探索RILP基因的生物学功能。方法 收集重庆医科大学附属长寿人民医院88例肺癌患者的癌组织和癌旁组织标本,分别用免疫组化染色、荧光定量PCR检测RILP蛋白及mRNA表达水平。选取肺癌细胞系(H1299、A549、H358、H19936和H460)和正常肺上皮细胞系(BEAS-2B),用荧光定量PCR检测RILP mRNA表达水平。用甲基化特异性PCR检测肺癌组织及细胞中RILP的甲基化。分析肺癌患者一般临床资料与RILP甲基化的关系。用空载体或人源RILP表达载体转染A549细胞,用克隆形成实验检测细胞增殖活性。结果 肺癌组织RILP高表达率为13.64%,低于癌旁组织的76.14%(P <0.05),癌旁组织RILP mRNA表达水平高于肺癌组织(P <0.05),正常肺上皮细胞系中RILP mRNA表达水平均高于肺癌细胞系(P <0.05)。与正常肺上皮细胞系相比,RILP基因在肺癌细胞系中出现了明显的甲基化。60.23%(53/88)的肺癌患者发生RILP基因甲基...     

ADAM23、αvβ3在非小细胞肺癌中的表达及临床意义

目的研究ADAM23、αvβ3在非小细胞肺癌中的表达及其与患者临床病理特征的关系。方法应用免疫组化和RT-PCR方法检测52例非小细胞肺癌及其配对癌旁组织和8例良性病变组织中ADAM23、αvβ3的表达。结果非小细胞肺癌中ADAM23蛋白的阳性率(38.5%)低于癌旁组织(86.5%)及肺良性病变组织(87.5%)(P0.05),而αvβ3蛋白的阳性率(80.8%)高于癌旁组织(26.9%)及肺良性病变组(37.5%)(P0.05)。ADAM23蛋白在非小细胞肺癌中的表达与患者的年龄、性别、肿瘤大小以及组织学分型无关,而与分化程度、淋巴结转移和临床分期关系密切;αvβ3蛋白在非小细胞肺癌中的表达与患者的年龄、性别、组织学分型以及分化程度无关,而与肿瘤的大小、淋巴结转移和临床分期有关;RT-PCR结果显示AD-AM23mRNA在非小细胞肺癌中的表达与癌旁组织和肺良性病变组织无明显差异,而αv、β3在癌中的表达高于癌旁组织及肺良性病变组织;ADAM23和αvβ3的表达呈负相关(χ2=9.026,r=-0.417,P0.05)。结论 ADAM23在非小细胞肺癌中低表达,αvβ3表达增高,二者可能在肺癌的侵袭和转移中发挥重要作用,并且具有协同性。     

长链非编码RNA-LINC00485在肺癌中的表达及对细胞增殖和迁移的影响

目的观察长链非编码RNA-LINC00485(LINC00485)在肺癌细胞株及组织中的表达,探讨其对肺癌细胞增殖和迁移的影响及其作用机制。方法采用qRT-PCR检测LINC00485在4种肺癌细胞株(H1975、A549、HCC827、H1299)、正常肺泡上皮细胞HPAEPIC和12例肺癌组织及癌旁组织中的差异性表达。通过生物信息学方法预测LINC00485可能结合的微小RNA(miRNA)及靶基因,将靶向沉默LINC00485的小干扰RNA(siRNA)通过脂质体转染至HCC827细胞。应用qRT-PCR检测LINC00485、miR-361-5p、p21活化蛋白激酶2(PAK2) mRNA的表达水平。采用Western blot法检测PAK2蛋白的表达水平。应用MTS法检测细胞增殖能力、细胞划痕实验检测细胞迁移能力。结果与正常肺泡上皮相比,LINC00485在肺癌细胞株中均呈高表达(P 0. 05),其中在HCC827细胞中表达水平最高。LINC00485在肺癌组织中的表达水平高于其癌旁组织(P 0. 01)。下调HCC827细胞LINC00485的表达后,miR-361-5p的表达上调(P 0. 01),PAK2 mRNA和蛋白的表达下调(P 0. 01),HCC827细胞增殖能力降低(P 0. 05),细胞迁移能力下降(P 0. 01)。结论 LINC00485在肺癌细胞株和组织中表达升高,下调LINC00485可通过调控miR-361-5p和PAK2基因的表达,抑制肺癌HCC827细胞的增殖和迁移能力。     

Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival

Introduction: miR-32 has recently been found to be implicated in many critical processes in various types of human cancer. However, its clinical significance in human non-small cell lung cancer (NSCLC) has not yet been elucidated. In the present study, we investigated the expression of miR-32 in NSCLC and analyzed its association with clinical features and prognosis of NSCLC patients. Methods: Quantitative real-time PCR (qRT-PCR) was used to measure expression level of miR-32 in lung cancer cell lines, normal bronchial epithelial cells, 90 pairs of tumor samples and adjacent non-tumor tissues. To determine its prognostic value, overall survival was evaluated using the Kaplan-Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis. Results: The expression of miR-32 was significantly decreased in lung cancer cell lines and NSCLC tissues compared with normal bronchial epithelial cells and adjacent non-tumor tissues (P < 0.05). This reduction of miR-32 was associated with tumor stage and lymph node metastasis (P < 0.05). Moreover, Kaplan-Meier analysis demonstrated that patients with low miR-32 expression had shorter overall survival time than those with high miR-32 expression (P < 0.05). Univariate analysis revealed statistically significant correlations between overall survival and miR-32 level, tumor stage and lymph node metastasis (P < 0.05). Furthermore, miR-32 levels, tumor stage and lymph node metastasis were independently associated with overall survival (P < 0.05). Conclusions: Our results provided the first evidence that down-regulation of miR-32 was correlated with NSCLC progression, and miR-32 might be a potential molecular biomarker for predicting the prognosis of patients.     

Down-regulation of microRNA-126 and microRNA-133b acts as novel predictor biomarkers in progression and metastasis of non small cell lung cancer

Objective: MiRNAs play crucial roles in progression of cancer. However, the underlying mechanisms of miRNAs in non small cell lung cancer are still poorly understood. The aim of this study was to investigate the expression level of microRNA-126 (miR-126) and microRNA-133b (miR-133b) and also their association with clinicopathological features in patients with non small cell lung cancer (NSCLC). Methods: Total RNA was purified from NSCLC tissues and adjacent non-tumor tissues and then quantitative real-time PCR (qRT-PCR) was used to evaluate the expression rate of microRNAs. Furthermore, the association of miR-126 and miR-133b level with clinicopathological features and prognosis were evaluated. Results: Our findings showed that expression of miR-126 was decreased in NSCLC tissues compared with adjacent non-tumor tissues. On the other hand, a lower expression of miR-133b was seen in NSCLC tissues when compared with adjacent non-tumor tissues. In term of miR-126, our results showed that miR-126 was associated with tumor stage and lymph nodes metastasis (P<0.05). In term of miR-133b, our finding indicated that decreased expression of miR-133b was correlated with advanced tumor stage and lymph nodes metastasis (P<0.05). Kaplan-Meier analysis and log-rank test indicated that patients with low expression of miR-126 and miR-133b had a shorter overall survival (log-rank test; P<0.05). Multivariate Cox proportional hazards model revealed that low expression of miR-126 and miR-133b, advanced tumor stage and lymph nodes metastasis were independent prognostic factors for overall survival of NSCLC patients. Conclusions: These findings suggested that miR-126 and miR-133b might play a key role in the progression and metastasis of NSCLC and would be applied as a novel therapeutic agent.     

Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival

Introduction: Recent studies have revealed that flotillin-2 (FLOT2) played important roles in cancer progression. The aim of this study was to investigate the clinicopathologic and prognostic significance of FLOT2 expression in human non-small cell lung cancer (NSCLC). Methods: Quantitative real-time PCR (qRT-PCR) was performed to detect FLOT2 mRNA expression in lung cancer cell lines, normal bronchial epithelial cells, 24 pairs of NSCLC tissues and matched adjacent non-tumor tissues. Immunohistochemistry (IHC) was performed to examine FLOT2 protein expression in paraffin-embedded tissues from 90 NSCLC patients. Statistical analyses were performed to evaluate the clinicopathological significance of FLOT2 expression. Results: FLOT2 mRNA expression was evidently up-regulated in lung cancer cell lines and NSCLC tissues compared with normal bronchial epithelial cells and adjacent non-tumor tissues. In the 90 cases of tested NSCLC samples, FLOT2 protein level was positively correlated with tumor stage, and lymph node metastasis. Patients with high FLOT2 expression had shorter overall survival compared with the low FLOT2 expression group. Univariate and multivariate analyses indicated that high FLOT2 expression was an independent poor prognostic factor for NSCLC patients. Conclusions: Our findings provided that high FLOT2 expression was associated with poor outcomes in NSCLC patients, and FLOT2 could be a potential prognostic biomarker for lung cancer progression.     

Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer

Introduction: MicroRNA-124 (miR-124) has been proven dysregulated in several human malignancies and correlated with tumor progression. However, its expression and clinical significance in non-small cell lung cancer (NSCLC) is still unclear. Thus, the aim of this study was to investigate the clinical significance of miR-124 expression in NSCLC. Methods: Expression levels of miR-124 in 92 pairs of NSCLC and adjacent non-tumor tissues were detected by quantitative real-time PCR (qRT-PCR). In order to determine its prognostic value, overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. Results: miR-124 expression level was significantly lower in NSCLC tissues compared with adjacent non-tumor tissues (P < 0.05). The 5-year OS of low miR-124 expression group was significantly shorter than that of high miR-124 expression group (P < 0.05). Moreover, the 5-year DFS of low miR-124 expression group was also significantly shorter than that of high miR-124 expression group (P < 0.05). In a multivariate Cox model, we found that miR-124 expression was an independent prognostic factor for both 5-year OS and 5-year DFS in NSCLC (P < 0.05). Conclusions: Our results offer the convincing evidence that miR-124 may play key roles in the progression of lung cancer and that the down-regulated expression of miR-124 may be independently associated with shorter OS and DFS of patients, suggesting that miR-124 might be a potential marker for further risk stratification in the treatment of lung cancer.     

MicroRNA-153 expression and prognosis in non-small cell lung cancer

Background: miR-153 has been found to be significantly decreased in non-small cell lung cancer (NSCLC) tissues; however, its clinical significance has not been investigated. Methods: The expression patterns of miR-153 in 137 pairs of human lung cancer tissues and adjacent normal lung tissues were analyzed using qRT-PCR. The relationships between miR-153 expression and clinicopathological parameters were examined by chi-square test. Kaplan-Meier method and the log-rank test were used to determine the difference in overall survival (OS) rates between two groups. Results: The expression of miR-153 was reduced significantly, compared with adjacent normal lung tissues (P<0.05). We observed that the expression level of miR-153 was positively correlated with the clinical stage (P=0.005), lymph node status (P=0.014), distant metastasis (P=0.004), and differentiated degree (P<0.001) in NSCLC patients. According to the Kaplan-Meier survival analysis, the patients with low miR-153 expression exhibited evidently poorer overall survival rates than those with high miR-153 expression (P=0.003). Multivariate analysis showed that the expression of miR-153 was an independent and significant factor associated with poor OS rates (P=0.002). Conclusion: Decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC, and further studies would be needed to prove our findings.     

Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma

Aims: The present study was designed to evaluate the different expression of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) in hepatocellular carcinoma (HCC) tissues and the adjacent normal tissues, further explore the correlation between UHRF1 expression and the prognosis of HCC patients. Methods: The UHRF1 expression at protein level in HCC tissues and the adjacent normal tissues were measured by high performance liquid chromatography (HPLC). Chi-square test was used to estimate the relationship between UHRF1 expression and clinicopathologic characteristics of HCC patients. The overall survival of HCC patients with diverse expression of UHRF1 was measured by Kaplan-Meier analysis. Cox regression analysis was conducted to judge the prognostic value of UHRF1 in HCC patients. Results: The UHRF1 was over-expressed in HCC tissues compared with the adjacent normal tissues according to the outcome of HPLC (P<0.001). Besides, the UHRF1 expression was tightly related to distant metastasis, cancer area, and HBV (P<0.05), but shared no correlation with gender, cirrhosis, and bilirubin (P>0.05). Patients with high UHRF1 expression had a shorter overall survival time than those with low UHRF1 expression (P<0.001). Cox regression analysis showed that UHRF1 was significantly linked with the prognosis of HCC patients (P=0.002, HR=5.807, 95% CI=1.901-17.742). Conclusion: UHRF1 was over-expressed in HCC tissues compared to the adjacent normal tissues and UHRF1 expression shared significant relevance with distant metastasis, cancer area and HBV. It could be an important and independent prognostic biomarker for HCC patients.     

MicroRNA-148b is down-regulated in non-small cell lung cancer and associated with poor survival

Background: The aim of this study was to clarify the clinicopathological significance of miRNA-148b (miR-148b) expression in NSCLC, and to explore the correlation between miR-148b level and the prognosis of patients with NSCLC. Methods: 151 patients diagnosed with NSCLC between May 2007 and April 2012 were included in the present study. Real-time RT-PCR method was used to assess the expression levels of miR-148b. The differences between two groups were assessed using Student’s t -test, and the Kaplan-Meier method was used to estimate overall survival. Results: The expression of miR-148b was decreased in tumor tissues compared to corresponding adjacent normal lung tissues (0.37 ± 0.12 vs. 1.00 ± 0.53, P < 0.05). Low miR-148b expression was significantly associated with TNM stage (P = 0.014), lymph node metastasis (P = 0.031), and distant metastasis (P = 0.008). Kaplan-Meier survival analysis showed that patients with low expression of miR-148b had significantly worse overall survival rates compared with those who had cancers with high miR-148b expression (log-rank test P = 0.039). Furthermore, multivariate Cox proportional hazards model analysis showed that miR-148b expression was independently associated with overall survival of patients with NSCLC (HR = 2.357, 95% CI: 1.612-9.212, P = 0.011). Conclusion: our data indicate that decreased expression of miR-148b in NSCLC tissues has prognostic value.     

Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma

Introduction: Long non-coding RNA MEG3 (lncRNA MEG3) has been showed to involve in a variety of cancers. However, the association between lncRNA MEG3 expression level and the prognosis of osteosarcoma is still unclear. Methods: The expression levels of lncRNA MEG3 in osteosarcoma tissues and adjacent non-tumor tissues were detected using quantitative real-time PCR (qRT-PCR). Differences in patient survival were determined using the Kaplan-Meier method and a log-rank test. A Cox proportional hazards regression analysis was used for univariate and multivariate analyses of prognostic values. Results: Our findings showed that expression of lncRNA MEG3 was clearly lower in osteosarcoma tissues compared with adjacent non-tumor tissues. The expression of lncRNA MEG3 was associated with clinical stage and distant metastasis (P<0.05). Kaplan-Meier analysis showed that patients with low lncRNA MEG3 expression had a shorter overall survival (log-rank test, P<0.05). Furthermore, multivariate analysis revealed that decreased expression of lncRNA MEG3, advanced clinical stage and distant metastasis were all independent predictors to overall survival of osteosarcoma patients. Conclusions: Downregulation of lncRNA MEG3 was associated with poor overall survival of osteosarcoma. LncRNA MEG3 could be a useful biomarker for progression and prognosis of osteosarcoma.